Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta
Advertisement
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.
These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain (DPNP).
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Isentio AS is expanding and opens office in Silicon Valley, USA
Pharminox appoints Scientific Advisory Board

An ultra-stable protein nanowire made by bacteria provides clues to combating climate change
Genzyme Expands its Research and Manufacturing Presence in Massachusetts - Starts Construction of State-of-the-Art Science Building in Framingham

Material loss protects teeth against fatigue failure - Computer simulation shows that the reduction of natural dental wear might be the main cause for widely spread non-carius cervical lesions in our teeth
